Background: Post-transplant hypertension is a major modifiable risk factor for graft and patient survival. The aim of this study was to establish independent predictors for achieving systolic, diastolic and overall blood pressure target [Kidney Disease Outcome Quality Initiative (K/DOQI) target blood pressure <130/80 mm Hg] in renal-transplant recipients (RTRs) and to consider whether current management strategies are adequate to achieve this aim. Methods: The most recent office blood pressure readings were collected for 513 RTRs at least 6 months after transplantation. In addition, demographic data, comorbidities, medications prescribed, weight, duration of transplantation, and laboratory parameters were recorded. Logistic regression analysis was used to determine whether any covariables were significant (p < 0.05) independent predictors of controlled blood pressure (<130/80 mm Hg). Results: Approximately 50% of the RTRs had blood pressures <130/80. There was a marked terminal digit preference demonstrated. Subjects who were female, had diabetes, did not have heart disease or had a lower albumin:creatinine ratio had a higher probability to achieve good blood pressure control. Diabetics were more likely to be prescribed 3 or more antihypertensive agents. Conclusions: This study shows that improvements in blood pressure control can be achieved. People with diabetes were 2.1 times more likely to meet target blood pressure. Further improvements in blood pressure control may require different treatment strategies in addition to the current pharmacological approach.

Keywords:
Cross-sectional study, Independent predictors, Post-transplant hypertension, Office blood pressure, Digit preference
1.
Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K: Comparison of survival probabilities for dialysis patients vs. cadaveric renal transplant recipients. JAMA 1993;270:1339–1343.
2.
Aakhus S, Dahl K, Widerøe TE: Cardiovascular disease in stable renal transplant recipients in Norway: morbidity and mortality during a 5-yr follow-up. Clin Transplant 2004;18:596–604.
3.
Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK: Long-term survival in renal transplant recipients with graft function. Kidney Int 2000;57:307–313.
4.
Opelz G, Döhler B: Improved long-term outcomes after renal transplantation associated with blood pressure control: collaborative transplant study. Am J Transplant 2005;5:2725–2731.
5.
Kasiske BL, Anjum S, Shah R, et al: Hypertension after kidney transplantation. Am J Kidney Dis 2004;43:1071–1081.
6.
K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 2004;43(suppl 1):S11–S13.
7.
Williams B, Poulter NR, Brown MJ, et al: British Hypertension Society Guidelines for Hypertension Management 2004 (BHS-IV): summary. Br Med J 2004;328:634–640.
8.
Levey AS, Greene T, Schluchter MD, et al: Glomerular filtration rate measurements in clinical trials: Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol 1993;4:1159–1171.
9.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J: Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217–223.
10.
First MR, Neylan JF, Rocher LL, Tejani A: Hypertension After Renal Transplantation. J Am Soc Nephrol 1994;4(suppl 1):30–36.
11.
Textor SC, Canzanello VJ, Taler SJ, et al: Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994;69:1182–1193.
12.
Opelz G, Wujciak T, Ritz E: Association of chronic kidney graft failure with recipient blood pressure: Collaborative Transplant Study. Kidney Int 1998;53:217–222.
13.
Bertoni E, Rosati A, Larti A, et al: Chronic kidney disease is still present after renal transplantation with excellent function. Transplant Proc 2006;38:1024–1025.
14.
European Best Practice Guidelines for renal transplantation. Section IV: Long-term management of the renal transplant recipient. IV.5.2: Cardiovascular risks. Arterial hypertension. Nephrol Dial Transplant 2002;17(suppl 4):25–26.
15.
Abbud-Filho M, Adams PL, Alberú J, et al: A report of the Lisbon Conference on the Care of the Kidney Transplant Recipient. Transplantation 2007;83:S1–S22.
16.
Mancia G, de Backer G, Dominiczak A, et al: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).7.6: Non-diabetic renal disease. J Hypertens 2007;25:1105–1187.
17.
Wen SW, Kramer MS, Hoey J, Hanley JA, Usher RH: Terminal digit preference, random error, and bias in routine clinical measurement of blood pressure. J Clin Epidemiol 1993;46:1187–1193.
18.
Wingfield D, Cooke J, Thijs L, et al: Terminal digit preference and single-number preference in the Syst-Eur trial: influence of quality control. Blood Press Monit 2002;7:169–177.
19.
Jami P, Smith P, Moningi SMV, Martin SA, Rosencrance G, Reyes BJ: Compliance with Joint National Committee 7 Guidelines in hypertension management in a teaching institution. Am J Med Qual 2007;22:251–258.
20.
UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998;317:713–720.
21.
van den Arend IJM, Stolk RP, Rutten GEHM, Schrijvers GJP: Education integrated into structured general practice care for type 2 diabetic patients results in sustained improvement of disease knowledge and self-care. Diabet Med 2000;17:190–197.
22.
Tutone VK, Mark PB, Stewart GA, et al: Hypertension, antihypertensive agents and outcomes following renal transplantation. Clin Transplant 2005;19:181–192.
23.
Mehrens T, Thiele S, Suwelack B, Kempkes M, Hohage H: The beneficial effect of calcium channel blockers on long-term kidney transplant survival are independent of blood-pressure reduction. Clin Transplant 2000;14:257–261.
24.
Paoletti E, Cassottana P, Amidone M, Gherzi M, Rolla D, Cannella G: ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial. Am J Kidney Dis 2007;50:133–142.
25.
Halimi J-M, Giraudeau B, Buchler M, et al: Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial. Clin Transplant 2007;21:277–284.
26.
Boots JM, van Duijnhoven EM, Christiaans MH, Nieman FH, van Suylen RJ, van Hooff JP: Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Transplant Int 2001;14:370–383.
27.
Vincenti F: Tacrolimus (FK 506) in kidney transplantation: five-year survival results of the US Multicenter, Randomized, Comparative Trial. Transplant Proc 2001;33:1019–1020.
28.
Cheung CY, Wong KM, Chan HW, et al: Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients. Transplant Int 2006;19:657–666.
29.
Ekberg H, Tedesco-Silva H, Demirbas A, et al: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562–2575.
30.
Walsh JM, Sundaram V, McDonald K, Owens DK, Goldstein MK: Implementing effective hypertension quality improvement strategies: barriers and potential solutions. J Clin Hypertens 2008;10:311–316.
31.
Mason J, Khunti K, Stone M, Farooqi A, Carr S: Educational interventions in kidney disease care: a systematic review of randomized trials. Am J Kidney Dis 2008;51:933–951.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.